Antidepressant study design affects patient expectancy: A pilot study

Psychological Medicine

Volumn 40, Issue 5, 2010, Pages 781-788

  Rutherford, B ^a   Sneed, J ^a   Devanand, D ^a   Eisenstadt, R ^a   Roose, S ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Clinical trial design; Comparator; Depression; Patient expectancy; Placebo effect; Placebo controlled

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LEARNING; MAJOR DEPRESSION; MALE; METHODOLOGY; MIDDLE AGED; PERSONALITY TEST; PILOT STUDY; PLACEBO EFFECT; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; STATISTICS; TREATMENT OUTCOME;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PILOT PROJECTS; PLACEBO EFFECT; PSYCHOMETRICS; RESEARCH DESIGN; SET (PSYCHOLOGY); TREATMENT OUTCOME;

EID: 77952430843     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291709991085     Document Type: Article

References (31)

1. Beck AT, Ward CH, Mendelson M (1961). An inventory of measuring depression. Archives of General Psychiatry 4, 53-63.
2. Benedetti F, Maggi G, Lopiano L, Lanotte M, Rainero I, Vighetti S, Pollo A (2003). Open versus hidden medical treatments: the patient's knowledge about a therapy affects the therapy outcome. Prevention and Treatment 6 (http://journals.apa.org/journals/pre/6/1/1a.html).
3. Borkovec TD, Costello E (1993). Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder. Journal of Consulting and Clinical Psychology 61, 611-619.
4. Borkovec TD, Nau SD (1972). Credibility of analogue therapy rationales. Journal of Behavioral Therapy and Experimental Psychiatry 3, 257-260.
5. Cohen J, Cohen P, West SG, Aiken LS (2003). Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences, 3rd edn. Lawrence Erlbaum Associates: New York.
6. Devilly GJ, Borkovec TD (2000). Psychometric properties of the credibility/expectancy questionnaire. Journal of Behavioral Therapy and Experimental Psychiatry 31, 73-86.
7. Guy W (1976). Clinical Global Impressions. New Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology, pp. 218-222. National Institute of Mental Health: Rockville, MD.
8. Hamilton MW (1960). A rating scale for depression. Journal of Neurology and Neurosurgical Psychiatry 23, 56-60.
9. Haour F (2005). Mechanisms of the placebo effect and of conditioning. Neuroimmunomodulation 12, 195-200.
10. Jiang W, Krishnan RR, O'Connor CM (2002). Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs 16, 111-127.
11. Kemeny ME, Rosenwasser LJ, Panettieri RA, Rose R, Berg-Smith S, Kline J (2007). Placebo response in asthma: a robust and objective phenomenon. Journal of Allergy and Clinical Immunology 119, 1375-1381.
12. Kennedy N, Paykel ES (2004). Residual symptoms at remission from depression: impact on long-term outcome. Journal of Affective Disorders 80, 135-144.
13. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS (2003). The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). Journal of the American Medical Association 289, 3095-3105.
14. Kessler RC, Chiu WT, Demler O, Walters EE (2005). Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry 62, 617-627. (Pubitemid 40973437)
15. Kirsch I (1997). Specifying nonspecifics: psychological mechanisms of placebo effects. In The Placebo Effect: An Interdisciplinary Exploration (ed. A. Harrington), pp. 166-183. Harvard University Press: Cambridge, MA.
16. Kirsch I, Deacon BJ, Huedo-Medina TB, Scorboria A, Moore TJ, Johnson BT (2008). Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. Public Library of Science Medicine 5, 260-268.
17. Kirsch I, Sapirstein G (1998). Listening to prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevention and Treatment 1 (http://journals.apa.org/prevention/volumeI/pre0010002a.html).
18. Krell HV, Leuchter AF, Morgan M, Cook IA, Abrams M (2004). Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant. Journal of Clinical Psychiatry 65, 1174-1179.
19. Lick J, Bootzin R (1975). Expectancy factors in the treatment of fear: methodological and theoretical issues. Psychological Bulletin 82, 917-931.
20. Marmar C, Gaston L (1998). The California Pharmacotherapy Alliance Scale. Unpublished manual.
21. Noble LM, Douglas BC, Newman SP (2001). What do patients expect of psychiatric services? A systematic and critical review of empirical studies. Social Science and Medicine 52, 985-998.
22. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A (1995). Residual symptoms after partial remission: an important outcome in depression. Psychological Medicine 25, 1171-1180.
23. Pollo A, Torre E, Lopiano L, Rizzone M, Lanotte M, Cavanna A, Bergamasco B, Benedetti F (2002). Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients. NeuroReport 13, 1383-1386.
24. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry 163, 1905-1917.
25. Rutherford BR, Sneed JR, Roose SP (2009). Does study design affect outcome? The effects of placebo control and treatment duration in antidepressant trials. Psychotherapy and Psychosomatics 78, 172-181.
26. Sneed JR, Rutherford BR, Rindskopf D, Roose SP (2008). Design makes a difference: antidepressant response rates in placebo-controlled versus comparator trials in late life depression. American Journal of Geriatric Psychiatry 16, 65-73.
27. Sotsky AM, Glass DR, Shea MT, Pilkonis PA, Collins F, Elkin I, Watkins JT, Imber SD, Leber WR, Moyer J, Oliveri ME (1991). Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. American Journal of Psychiatry 148, 997-1008.
28. Ventura J, Liberman RP, Green MF, Shaner A, Mintz J (1998). Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P). Psychiatry Research 79, 163-173.
29. Walsh BT, Seidman SN, Sysko R, Gould M (2002). Placebo response in studies of major depression: variable, substantial, and growing. Journal of the American Medical Association 287, 1840-1847.
30. Wilkins W (1973). Expectancy of therapeutic gain: an empirical and conceptual critique. Journal of Consulting and Clinical Psychology 40, 69-77.
31. WHO (2004). The World Health Report 2004: Changing History, Annex Table 3: Burden of disease in DALYs by cause, sex, and mortality stratum in WHO regions, estimates for 2002. World Health Organization: Geneva.